REG - Imaging Biometrics - Director/PDMR Dealing
09/07/2025 17:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nRSI4320Qa&default-theme=true
RNS Number : 4320Q Imaging Biometrics Limited 09 July 2025
Imaging Biometrics Limited
("IB" or the "Company")
PDMR dealing
Imaging Biometrics Limited, a leader in quantitative imaging solutions and
novel therapies for CNS malignancies, announces that it has been notified of
the following transactions in ordinary shares in the Company undertaken by
directors/persons discharging managerial responsibility (PDMR).
The notification below is made in accordance with Article 19(3) of the Market
Abuse Regulation.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Michael Schmainda
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer, or auction monitor
a) Name Imaging Biometrics, Ltd
b) LEI 213800SPW48XRJS2QH57
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of £0.01 each in Imaging Biometrics, Ltd
Identification code JE00BD4H0R42
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
0.7 pence 200,000 Ordinary Shares
d) Aggregated information
- Aggregated volume 200,000
- Price £1400
e) Date of the transaction 09/07/2025
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEAKXNEFASEFA